BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 9001896)

  • 1. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M; Brunner HR
    Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advantages of angiotensin II antagonism.
    Burnier M; Waeber B; Brunner HR
    J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
    Brunner HR; Nussberger J; Waeber B
    J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M; Suzuki H; Naitoh M; Matsumoto A; Kageyama Y; Tsujimoto G; Saruta T
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future role of losartan.
    Hansson L
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: effects on renal function.
    Jover B; Mimran A
    J Hypertens Suppl; 1994 Nov; 12(9):S3-9. PubMed ID: 7884582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
    Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
    Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
    Burnier M; Pechère-Bertschi A; Nussberger J; Waeber B; Brunner HR
    Am J Kidney Dis; 1995 Jul; 26(1):108-15. PubMed ID: 7611241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Localization of components of the renin-angiotensin system and site of action of inhibitors.
    Chai SY; Zhuo J; Mendelsohn FA
    Arzneimittelforschung; 1993 Feb; 43(2A):214-21. PubMed ID: 8498967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new class of therapeutic agents: the angiotensin II receptor antagonists.
    Timmermans PB; Smith RD
    Cardiologia; 1994 Dec; 39(12 Suppl 1):397-400. PubMed ID: 7634303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the specific angiotensin II receptor antagonist losartan on urate homeostasis and intestinal urate transport.
    Hatch M; Freel RW; Shahinfar S; Vaziri ND
    J Pharmacol Exp Ther; 1996 Jan; 276(1):187-93. PubMed ID: 8558429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of losartan, the first angiotensin II receptor antagonist.
    Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diversified pharmacology of angiotensin II-receptor blockade.
    Timmermans PB; Smith RD
    Blood Press Suppl; 1996; 2():53-61. PubMed ID: 8913541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II antagonists: a new class of antihypertensive agent.
    Waeber B; Brunner HR
    Br J Clin Pract; 1996; 50(5):265-8. PubMed ID: 8794603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
    Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
    Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
    Leary AC; MacDonald TM
    Int J Clin Pract; 1998 Oct; 52(7):475-81. PubMed ID: 10622089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature.
    Ritter JM; Cockcroft JR; Sciberras DG; Goldberg MR
    J Hypertens Suppl; 1993 Apr; 11(3):S59-61. PubMed ID: 8391072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.